Adjunctive intracoronary antithrombotic therapy: time to revisit an old strategy?
Srinivasan
Manivannan
M
Division of Cardiovascular Diseases and Department of Internal Medicine Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Prasad
Abhiram
A
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003328:Coronary Thrombosis / Q000188:drug therapy*; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage; D010455:Peptides / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015607:Stents; D013300:Streptokinase / Q000008:administration & dosage; D015912:Thrombolytic Therapy / Q000379:methods*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D013300:Streptokinase; D000077542:Eptifibatide; D000077284:Abciximab